Cynthia Smith Buys 31,000 Shares of Protara Therapeutics
Insider Cynthia Smith purchased 31,000 shares of Protara Therapeutics on June 15, 2026.
Key Points
- Cynthia Smith purchased 31,000 shares of Protara Therapeutics on June 15, 2026, with no reported transaction value.
- Protara Therapeutics, trading at $3.94, has a market cap of $214.1 million and a 52-week range of $2.77 to $7.82.
- Analysts maintain a positive outlook with price targets between $24 and $30, reflecting confidence in the stock.
Cynthia Smith, an insider at Protara Therapeutics, Inc., bought 31,000 shares of the company on June 15, 2026. This transaction did not have a reported purchase price, aligning with several other insiders who made similar buys on the same day.
Insider Buying and Selling at Protara Therapeutics, Inc.
On June 15, 2026, several insiders, including Cynthia Smith, acquired 31,000 shares each in Protara Therapeutics. Other insiders making similar purchases include Barry Flannelly, Richard Levy, Michael Edward Solomon, Roger Garceau, and Jane Huang. These transactions were not part of any pre-planned trading programs.
Other Institutional Activity in Protara Therapeutics
In recent institutional activity, Janus Henderson Group PLC added 65,395 shares, bringing its total to over 5.2 million shares valued at roughly $27.2 million. BlackRock, Inc. significantly increased its stake by 986,100 shares, reaching nearly 3.4 million shares worth approximately $17.7 million. Millennium Management LLC also made a notable increase, adding over 2 million shares to hold about 2.8 million shares valued at $14.8 million. Meanwhile, Velan Capital Investment Management LP maintained its position with no changes, and Vanguard Capital Management LLC established a new position with over 2.1 million shares valued at $11 million.
Protara Therapeutics Stock Snapshot
Shares of NasdaqGM:TARA traded around $3.94. Protara Therapeutics has a market cap of about $214.1 million and a forward P/E ratio that is not meaningful due to its unprofitability. The stock's 52-week range spans from $2.77 to $7.82, with a 50-day moving average of $4.87 and a 200-day moving average of $5.26. The company maintains a strong financial position with a current ratio of 15.69 and a quick ratio of 15.39.
Analysts Set New Price Targets
Analysts remain optimistic about Protara Therapeutics. On May 20, 2026, Oppenheimer maintained its 'buy' rating with a price target of $28. JP Morgan also upheld its 'buy' rating with a $26 target on May 14, 2026. HC Wainwright & Co. reiterated a 'buy' rating with a $27 target on April 29, 2026. Overall, the consensus among seven analysts is a 'buy' rating, with an average target price of approximately $26.57.
About Protara Therapeutics
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, NY. It focuses on developing transformative therapies for cancer and rare diseases. Its lead program, TARA-002, is in Phase II trials for treating non-muscle invasive bladder cancer and lymphatic malformations. The company is also working on intravenous choline chloride as a phospholipid substrate replacement therapy. Under the leadership of CEO Jesse Shefferman, Protara Therapeutics employs 46 people.
Bottom Line
Cynthia Smith's recent purchase of Protara Therapeutics shares highlights insider confidence in the company's prospects. The stock is currently trading near its lower 52-week range, presenting a potentially attractive entry point for investors. Analysts continue to support the stock with 'buy' ratings and price targets reflecting a positive outlook. As always, it's important to remember that insider transactions are part of regular business activities and may not directly signal future stock performance.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.